ZACKS·2026-02-27 18:41Core Insights - Hims & Hers Health, Inc. (HIMS) operates a consumer-first, digitally native healthcare platform that provides personalized care through telehealth, online pharmacy, and subscription services, focusing on chronic conditions like sexual health, hormone health, weight loss, dermatology, and mental health [1] Group 1: Business Model and Services - The company integrates licensed providers, proprietary technology, and cloud pharmacy infrastructure to support recurring treatment for various health conditions [1] - Recently, Hims & Hers has expanded into proactive and preventative care, launching Labs for data-driven testing and a multi-cancer early detection test in collaboration with GRAIL [2] - New offerings include menopause and perimenopause services on the Hers platform and exclusive oral testosterone treatments for men's health [2] Group 2: International Expansion - HIMS has entered Canada through the acquisition of Livewell and expanded its weight loss program to the U.K. [3] - The company announced plans to acquire Eucalyptus to enhance its presence in Europe and expand into Australia and Japan [3] Group 3: Market Performance and Valuation - Hims & Hers shares have decreased by 65.4% over the past year, underperforming the industry decline of 29.1% [6] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 1.3X, significantly lower than the industry average of 3.8X and its five-year median of 2.7X [10] - The Zacks Consensus Estimate for HIMS' 2026 earnings per share suggests flat performance compared to 2025 [8]